Gary M. Clark
Dana-Farber Brigham Cancer Center · 291 works · 56,040 citations · h-index 88
Top works
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
- Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
- Prognostic Factors in Breast Cancer
- HER-2/neu oncogene protein and prognosis in breast cancer.
- Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
- Progesterone Receptors as a Prognostic Factor in Stage II Breast Cancer
- How To Use Prognostic Factors in Axillary Node-Negative Breast Cancer Patients
- HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
- Prediction of Relapse or Survival in Patients with Node-Negative Breast Cancer by DNA Flow Cytometry
- Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer
- REporting recommendations for tumour MARKer prognostic studies (REMARK)
- HER-2/neu amplification predicts poor survival in node-positive breast cancer.
- Cathepsin D and Prognosis in Breast Cancer
- Reporting Recommendations for Tumor Marker Prognostic Studies
- Tumor Biologic Factors and Breast Cancer Prognosis Among White, Hispanic, and Black Women in the United States
- Follow-up study of HER-2/neu amplification in primary breast cancer.